<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aims  To estimate the potential gain of national screening programmes for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) by stool occult blood testing in the Nordic countries, with comparative reference to the burden of other causes of premature <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Methods  Implementation of national screening programmes for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was modelled among people 55-74 years in accordance with the 2011 Cochrane review of biannual screening, using the faecal occult blood test (FOBT) for 10 years, resulting in 15% relative risk reduction in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:hpo ids='HP_0011420'>deaths</z:hpo> among <z:hpo ids='HP_0000001'>all</z:hpo> those invited [intention-to-treat; relative risk 0.85; confidence interval (CI) 0.78 to 0.92] </plain></SENT>
<SENT sid="2" pm="."><plain>Our calculations are based on the World Health Organization and national databanks on <z:hpo ids='HP_0011420'>death</z:hpo> causes (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10) and the mid-year number of inhabitants in the target group </plain></SENT>
<SENT sid="3" pm="."><plain>For Finland, Denmark, Norway and Sweden, we used data for 2009 </plain></SENT>
<SENT sid="4" pm="."><plain>For Iceland, due to the population's small size, we calculated mean mortality for the period 2005-2009 </plain></SENT>
<SENT sid="5" pm="."><plain>Results  Invitation to a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening programme for 10 years could influence 0.5-0.9% (95%CI 0.4-1.2) of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0011420'>deaths</z:hpo> in the age group 65-74 years </plain></SENT>
<SENT sid="6" pm="."><plain>Among the remaining 99% of premature <z:hpo ids='HP_0011420'>deaths</z:hpo>, around 50% were caused by <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, <z:e sem="disease" ids="C0339910" disease_type="Disease or Syndrome" abbrv="">other lung diseases</z:e>, <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> and accidents, with some national variations </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusions and implications  Establishment of a screening programme for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> for people aged 55-74 can be expected to affect only a minor proportion of <z:hpo ids='HP_0000001'>all</z:hpo> premature <z:hpo ids='HP_0011420'>deaths</z:hpo> in the Nordic setting </plain></SENT>
<SENT sid="8" pm="."><plain>From a public health perspective, prioritizing preventive strategies targeting more prevalent causes of premature <z:hpo ids='HP_0011420'>death</z:hpo> may be a superior approach </plain></SENT>
</text></document>